NASDAQ:MGTX MeiraGTx Q4 2024 Earnings Results & Report $9.89 +0.48 (+5.10%) Closing price 04:00 PM EasternExtended Trading$9.89 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. MeiraGTx missed analyst earnings expectations but beat on revenue in its Q4 2024 results, released March 13, 2025. The company reported EPS of -$0.50 versus the -$0.48 consensus estimate, while revenue of $21.39 million topped the $1.50 million estimate by $19.89 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 13, 2025TimeBefore Market OpensConference Call DateMarch 12, 2025Conference Call7:00 PM ET MeiraGTx EPS ResultsActual EPS-$0.50Consensus EPS -$0.48Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersMeiraGTx Revenue ResultsActual Revenue$21.39 millionExpected Revenue$1.50 millionBeat/MissBeat by +$19.89 millionYoY Revenue GrowthN/AUpcoming EarningsMeiraGTx's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) MeiraGTx Q4 2024 Earnings FAQ Did MeiraGTx beat earnings estimates for Q4 2024? MeiraGTx (NASDAQ:MGTX) reported earnings of -$0.50 per share for Q4 2024, missing the consensus estimate of -$0.48. The report was announced on Thursday, March 13, 2025. What was MeiraGTx's revenue for Q4 2024? MeiraGTx reported revenue of $21.39 million for Q4 2024, against a consensus estimate of $1.50 million. When is MeiraGTx's next earnings date? MeiraGTx's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for MeiraGTx on the company's earnings history page. MeiraGTx Earnings HeadlinesMeiraGTx: The Data Held Up, The Valuation Didn't (Rating Downgrade)October 14 at 10:37 AM | seekingalpha.comStoke Therapeutics (NASDAQ:STOK) vs. MeiraGTx (NASDAQ:MGTX) Critical ComparisonOctober 14 at 2:15 AM | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 15 at 1:00 AM | InvestorPlace (Ad)MeiraGTx Holdings plc (MGTX)October 7, 2026 | finance.yahoo.comXenetic Biosciences (NASDAQ:XBIO) & MeiraGTx (NASDAQ:MGTX) Financial ContrastOctober 7, 2026 | americanbankingnews.comGoldman Sachs Initiates MeiraGTx at Neutral With $16 Price TargetSeptember 24, 2026 | marketscreener.comMSee More MeiraGTx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email. Email Address About MeiraGTxMeiraGTx (NASDAQ:MGTX) (NASDAQ:MGTX) is a clinical-stage biotechnology company developing gene therapy and ribonucleic acid (RNA) medicines for diseases with significant unmet medical needs. Its research focuses primarily on the central nervous system, immune-mediated conditions and disorders affecting salivary gland function. The company’s technology platforms are designed to deliver therapeutic genes or regulate gene expression in targeted tissues. Its investigational programs have included gene therapies for Parkinson’s disease and radiation-induced xerostomia, a condition involving chronic dry mouth after cancer treatment. MeiraGTx has also pursued additional programs in neurological and other serious diseases, although its pipeline and development priorities may change as clinical studies progress. Founded in 2015, MeiraGTx has built research, development and manufacturing capabilities in the United States and the United Kingdom. The company is led by Alexandra Forbes, who co-founded MeiraGTx and serves as president and chief executive officer.View MeiraGTx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
